Donald J Buchsbaum

List of Publications by Year in Descending Order

193 papers	6,469 citations	43 h-index	70 g-index
201 ext. papers	7,204 ext. citations	4.9 avg, IF	5.47 L-index

#	Paper	IF	Citations
193	Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.. *Advances in Cancer Research*, **2022**, 153, 131-168	5.9	0
192	Glycosyltransferase ST6Gal-I promotes the epithelial to mesenchymal transition in pancreatic cancer cells. *Journal of Biological Chemistry*, **2021**, 296, 100034	5.4	14
191	PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. *Translational Oncology*, **2020**, 13, 100776	4.9	7
190	PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity. *Drug Discovery Today*, **2020**, 25, 1521-1527	8.8	7
189	B7-H3-targeted Radioimmunotherapy of Human Cancer. *Current Medicinal Chemistry*, **2020**, 27, 4016-4038	4.3	3
188	Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS. *MedComm*, **2020**, 1, 121-128	2.8	6
187	STAT3 and GR Cooperate to Drive Gene Expression and Growth of Basal-Like Triple-Negative Breast Cancer. *Cancer Research*, **2020**, 80, 4355-4370	10.1	5
186	Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer. *Therapeutic Advances in Medical Oncology*, **2020**, 12, 1758835920913798	5.4	10
185	Histone deacetylase inhibition promotes intratumoral CD8 T-cell responses, sensitizing murine breast tumors to anti-PD1. *Cancer Immunology, Immunotherapy*, **2019**, 68, 2081-2094	7.4	12
184	The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth. *Cancer Immunology, Immunotherapy*, **2019**, 68, 175-188	7.4	12
183	Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells. *Journal of Cellular Biochemistry*, **2018**, 119, 6216-6230	4.7	9
182	CD38 pretargeted RIT of B-cell tumors. *Blood*, **2018**, 131, 589-590	2.2	1
181	Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. *Nuclear Medicine and Biology*, **2018**, 58, 67-73	2.1	26
180	Retraction notice to "SRI36160 is a specific inhibitor of Wnt/-catenin signaling in human pancreatic and colorectal cancer cells" [Canc. Lett. 389C (2017) 41-48]. *Cancer Letters*, **2018**, 422, 131	9.9	
179	Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	19
178	Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	27
177	ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage. *Journal of Biological Chemistry*, **2018**, 293, 984-994	5.4	44

176	The antitumor effects of entinostat in ovarian cancer require adaptive immunity. *Cancer*, **2018**, 124, 4657-4666	6.4	11
175	Novel Biomimetic Microphysiological Systems for Tissue Regeneration and Disease Modeling. *Advances in Experimental Medicine and Biology*, **2018**, 1077, 87-113	3.6	1
174	Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer Cells. *Journal of Cellular Biochemistry*, **2017**, 118, 2285-2294	4.7	5
173	Retraction of "Design and Synthesis of Novel Cyclic Amine Benzimidazoles for the Treatment of Pancreatic Cancer". *Journal of Medicinal Chemistry*, **2017**, 60, 7615	8.3	2
172	B7-H3-targeted Pb radioimmunotherapy of ovarian cancer in preclinical models. *Nuclear Medicine and Biology*, **2017**, 47, 23-30	2.1	37
171	Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review. *Gynecologic Oncology Reports*, **2017**, 20, 81-86	1.3	31
170	SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cells. *Cancer Letters*, **2017**, 389, 41-48	9.9	7
169	Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology. *Oncology Reviews*, **2017**, 11, 332	4.3	26
168	Modulation of antitumor immunity with histone deacetylase inhibitors. *Immunotherapy*, **2017**, 9, 1359-1372	3.8	20
167	Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs. *Clinical and Translational Medicine*, **2017**, 6, 11	5.7	8
166	Genomic regulation of invasion by STAT3 in triple negative breast cancer. *Oncotarget*, **2017**, 8, 8226-8238	3.3	47
165	Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth. *Oncotarget*, **2017**, 8, 44159-44170	3.3	22
164	RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. *Molecular Oncology*, **2016**, 10, 1169-82	7.9	38
163	Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. *Cancer Immunology Research*, **2016**, 4, 390-9	12.5	66
162	SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. *Molecular Cancer Therapeutics*, **2016**, 15, 680-8	6.1	35
161	Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974. *Laboratory Investigation*, **2016**, 96, 249-59	5.9	46
160	A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of TRA-8/DR5 Oligomers Predicts TRA-8 Therapeutic Efficacy in Breast and Pancreatic Cancer Mouse Models. *Molecular Imaging and Biology*, **2016**, 18, 325-33	3.8	3
159	Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer. *Oncotarget*, **2016**, 7, 17991-8005	3.3	19

158	Role of nanotechnology and gene delivery systems in TRAIL-based therapies. *Ecancermedicalscience* , **2016**, 10, 660	2.7	13
157	Niclosamide and its analogs are potent inhibitors of Wnt/Ecatenin, mTOR and STAT3 signaling in ovarian cancer. *Oncotarget*, **2016**, 7, 86803-86815	3.3	48
156	Surveying the serologic proteome in a tissue-specific kras(G12D) knockin mouse model of pancreatic cancer. *Proteomics*, **2016**, 16, 516-31	4.8	24
155	The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype. *Cancer Research*, **2016**, 76, 3978-88	10.1	96
154	Ovarian cancer and the immune system - The role of targeted therapies. *Gynecologic Oncology*, **2016**, 142, 349-56	4.9	41
153	Characterization of the Interactions between Calmodulin and Death Receptor 5 in Triple-negative and Estrogen Receptor-positive Breast Cancer Cells: AN INTEGRATED EXPERIMENTAL AND COMPUTATIONAL STUDY. *Journal of Biological Chemistry*, **2016**, 291, 12862-12870	5.4	15
152	Ovarian and cervical cancer patient derived xenografts: The past, present, and future. *Gynecologic Oncology*, **2015**, 138, 486-91	4.9	34
151	Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer. *Journal of the Egyptian National Cancer Institute*, **2015**, 27, 205-15	1.9	6
150	S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase. *Scientific Reports*, **2015**, 5, 8453	4.9	34
149	Dynamic contrast enhanced magnetic resonance imaging of an orthotopic pancreatic cancer mouse model. *Journal of Visualized Experiments*, **2015**,	1.6	7
148	Niclosamide Analogs for Treatment of Ovarian Cancer. *International Journal of Gynecological Cancer* , **2015**, 25, 1377-85	3.5	17
147	Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. *Gynecologic Oncology*, **2014**, 132, 203-10	4.9	30
146	Recurrent read-through fusion transcripts in breast cancer. *Breast Cancer Research and Treatment*, **2014**, 146, 287-97	4.4	106
145	Effect of niclosamide on basal-like breast cancers. *Molecular Cancer Therapeutics*, **2014**, 13, 800-11	6.1	62
144	Inhibition of Wnt/Ecatenin pathway by niclosamide: a therapeutic target for ovarian cancer. *Gynecologic Oncology*, **2014**, 134, 112-20	4.9	118
143	Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. *Cancer Letters*, **2014**, 349, 8-14	9.9	231
142	Pazopanib combined with radiation: in vivo model of interaction. *Cancer Biotherapy and Radiopharmaceuticals*, **2014**, 29, 247-50	3.9	6
141	Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer. *Cancer Biology and Therapy*, **2014**, 15, 1053-60	4.6	10

140	Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers. *Molecular Imaging and Biology*, **2014**, 16, 85-94	3.8	8
139	Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?. *World Journal of Stem Cells*, **2014**, 6, 441-7	5.6	44
138	The Wnt/β-catenin pathway in ovarian cancer: a review. *Gynecologic Oncology*, **2013**, 131, 772-9	4.9	313
137	Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma. *Annals of Surgical Oncology*, **2013**, 20, 3059-65	3.1	9
136	ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines. *Cancer Research*, **2013**, 73, 2368-78	10.1	113
135	Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers. *Molecular Cancer Therapeutics*, **2013**, 12, 2110-20	6.1	71
134	The C-terminal region Mesd peptide mimics full-length Mesd and acts as an inhibitor of Wnt/β-catenin signaling in cancer cells. *PLoS ONE*, **2013**, 8, e58102	3.7	12
133	The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells. *Gynecologic Oncology*, **2012**, 125, 226-30	4.9	20
132	A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. *Gynecologic Oncology*, **2012**, 127, 420-5	4.9	55
131	A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model. *Pancreas*, **2012**, 41, 789-96	2.6	13
130	Effect of anti-DR5 and chemotherapy on basal-like breast cancer. *Breast Cancer Research and Treatment*, **2012**, 133, 417-26	4.4	30
129	Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity. *Breast Cancer Research and Treatment*, **2012**, 133, 437-45	4.4	22
128	Chapter seven--Cancer treatment with gene therapy and radiation therapy. *Advances in Cancer Research*, **2012**, 115, 221-63	5.9	54
127	The use of retinoids in ovarian cancer: a review of the literature. *International Journal of Gynecological Cancer*, **2012**, 22, 191-8	3.5	4
126	Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation. *Radiotherapy and Oncology*, **2011**, 101, 183-9	5.3	3
125	Cellular model of Warburg effect identifies tumor promoting function of UCP2 in breast cancer and its suppression by genipin. *PLoS ONE*, **2011**, 6, e24792	3.7	103
124	Early Therapy Evaluation of Combined Cetuximab and Irinotecan in Orthotopic Pancreatic Tumor Xenografts by Dynamic Contrast-Enhanced Magnetic Resonance Imaging. *Molecular Imaging*, **2011**, 10, 7290.2010.00040	3.7	15
123	Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. *Gynecologic Oncology*, **2011**, 121, 193-9	4.9	9

122	DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy. *Molecular Imaging and Biology*, **2011**, 13, 94-103	3.8	23
121	Relationship between galectin-3 expression and TRAIL sensitivity in breast cancer. *Expert Review of Anticancer Therapy*, **2011**, 11, 1193-6	3.5	5
120	Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells. *Molecular Cancer Research*, **2011**, 9, 403-17	6.6	26
119	Combined modality therapy with TRAIL or agonistic death receptor antibodies. *Cancer Biology and Therapy*, **2011**, 11, 431-49	4.6	36
118	Thrombospondin-1 opens the paracellular pathway in pulmonary microvascular endothelia through EGFR/ErbB2 activation. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2011**, 301, L79-90	5.8	16
117	Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging. *Molecular Imaging*, **2011**, 10, 153-67	3.7	16
116	Drugs in clinical trials & future directions **2011**, 84-95		
115	A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer. *Pancreas*, **2010**, 39, 913-22	2.6	10
114	Cytosine Deaminase/5-Fluorocytosine Molecular Cancer Chemotherapy **2010**, 219-242		
113	KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model. *Clinical and Experimental Metastasis*, **2010**, 27, 591-600	4.7	47
112	Overcoming TRAIL resistance in ovarian carcinoma. *Gynecologic Oncology*, **2010**, 119, 157-63	4.9	23
111	Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1. *Molecular Pharmacology*, **2009**, 76, 81-90	4.3	86
110	Monoclonal antibodies in the treatment of pancreatic cancer. *Immunotherapy*, **2009**, 1, 223-9	3.8	31
109	Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. *Clinical Cancer Research*, **2009**, 15, 4058-65	12.9	52
108	Experimental cancer therapy using restoration of NAD+ -linked 15-hydroxyprostaglandin dehydrogenase expression. *Molecular Cancer Therapeutics*, **2009**, 8, 3130-9	6.1	24
107	In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts. *Orl*, **2009**, 71, 1-5	2	6
106	Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. *Gynecologic Oncology*, **2009**, 113, 384-90	4.9	28
105	Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. *Journal of Immunology*, **2009**, 182, 7548-57	5.3	57

104	Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model. *International Journal of Gynecological Cancer*, **2009**, 19, 814-9	3.5	13
103	Cancer gene therapy **2009**, 589-612		2
102	Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. *Gynecologic Oncology*, **2008**, 108, 591-7	4.9	17
101	Molecular targeted therapies for pancreatic cancer. *American Journal of Surgery*, **2008**, 196, 430-41	2.7	42
100	Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. *Vaccine*, **2008**, 26, 4314-9	4.1	15
99	Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. *Cancer Research*, **2008**, 68, 8369-76	10.1	43
98	Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene. *Molecular Cancer Therapeutics*, **2008**, 7, 2845-54	6.1	23
97	Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. *Clinical Cancer Research*, **2008**, 14, 2180-9	12.9	29
96	In Reply to Dr. Speer. *International Journal of Radiation Oncology Biology Physics*, **2008**, 72, 1274	4	
95	Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. *International Journal of Radiation Oncology Biology Physics*, **2008**, 71, 507-16	4	29
94	Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. *Gynecologic Oncology*, **2007**, 105, 291-8	4.9	37
93	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers. *Gynecologic Oncology*, **2007**, 106, 614-21	4.9	20
92	Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. *Surgery*, **2007**, 141, 464-9	3.6	56
91	Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. *Annals of Surgical Oncology*, **2007**, 14, 2150-8	3.1	31
90	Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. *Clinical Cancer Research*, **2007**, 13, 5535s-5543s	12.9	34
89	TRAIL-receptor antibodies as a potential cancer treatment. *Future Oncology*, **2007**, 3, 405-9	3.6	25
88	Single-photon emission computed tomography imaging with a humanized, Apoptosis-inducing antibody targeting human death receptor 5 in pancreas and breast tumor xenografts. *Cancer Biology and Therapy*, **2007**, 6, 1392-1398	4.6	3
87	ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. *Cancer Biology and Therapy*, **2007**, 6, 548-54	4.6	78

86	TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. *Molecular Cancer Therapeutics*, **2007**, 6, 3198-207	6.1	37
85	High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts. *Molecular Cancer Therapeutics*, **2007**, 6, 866-75	6.1	20
84	Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer. *Clinical Cancer Research*, **2007**, 13, 5643s-5645s	12.9	27
83	EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients. *Journal of Surgical Research*, **2007**, 143, 20-6	2.5	30
82	Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. *Gynecologic Oncology*, **2006**, 101, 46-54	4.9	45
81	Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function. *Cancer Research*, **2006**, 66, 8520-8	10.1	54
80	Gene delivery and gene therapy of prostate cancer. *Expert Opinion on Drug Delivery*, **2006**, 3, 37-51	8	6
79	Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. *Journal of Molecular Diagnostics*, **2006**, 8, 76-83	5.1	72
78	TRAIL receptor-targeted therapy. *Future Oncology*, **2006**, 2, 493-508	3.6	39
77	Pretargeted radioimmunotherapy. *International Journal of Radiation Oncology Biology Physics*, **2006** , 66, S57-9	4	24
76	Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo. *Journal of Gastrointestinal Surgery*, **2006**, 10, 1291-300; discussion 1300	3.3	16
75	Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein. *Clinical Cancer Research*, **2005**, 11, 8180-5	12.9	23
74	Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region. *Cancer Biotherapy and Radiopharmaceuticals*, **2005**, 20, 502-13	3.9	20
73	The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. *Journal of Biological Chemistry*, **2005**, 280, 11059-66	5.4	174
72	Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. *Clinical Cancer Research*, **2005**, 11, 8773-81	12.9	58
71	Radiotargeted gene therapy. *Journal of Nuclear Medicine*, **2005**, 46 Suppl 1, 179S-86S	8.9	8
70	Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer. *Molecular Therapy*, **2004**, 10, 1059-70	11.7	24
69	Gene expression imaging with radiolabeled peptides. *Annals of Nuclear Medicine*, **2004**, 18, 275-83	2.5	11

68	Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells. *International Journal of Radiation Oncology Biology Physics*, **2004**, 58, 950-8	4	11
67	Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression. *International Journal of Radiation Oncology Biology Physics*, **2004**, 59, 2-10	4	29
66	Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. *Journal of Gastrointestinal Surgery*, **2004**, 8, 960-9; discussion 969-70	3.3	36
65	Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure. *Bioconjugate Chemistry*, **2004**, 15, 1264-74	6.3	30
64	Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs. *Seminars in Nuclear Medicine*, **2004**, 34, 32-46	5.4	21
63	An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant glioma. *International Journal of Radiation Oncology Biology Physics*, **2003**, 55, 1037-50	4	31
62	Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. *Oncogene*, **2003**, 22, 2034-44	9.2	145
61	Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. *Bioconjugate Chemistry*, **2003**, 14, 302-10	6.3	70
60	Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. *Journal of Surgical Research*, **2003**, 111, 274-83	2.5	36
59	Three-dimensional dose model for the comparison of 177Lu-HuCC49DeltaCH2 and 177Lu-HuCC49 radioimunotherapy in mice bearing intraperitoneal xenografts. *Cancer Biotherapy and Radiopharmaceuticals*, **2003**, 18, 239-47	3.9	2
58	Cancer gene therapy **2003**, 583-613		1
57	Invited commentary: targeting of 125I-labeled B lymphocyte stimulator. *Journal of Nuclear Medicine* , **2003**, 44, 434-6	8.9	1
56	Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. *Clinical Cancer Research*, **2003**, 9, 3731-41	12.9	103
55	Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: a sensitive method for assessing 5-fluorocytosine toxicity in vitro. *Analytical Biochemistry*, **2002**, 301, 189-99	3.1	5
54	Targeted radiotherapy with [(90)Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector. *Cancer*, **2002**, 94, 1298-305	6.4	40
53	Rationales, evidence, and design considerations for fractionated radioimmunotherapy. *Cancer*, **2002**, 94, 1332-48	6.4	103
52	Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. *International Journal of Radiation Oncology Biology Physics*, **2002**, 54, 1180-93	4	100
51	Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells. *Molecular Therapy*, **2002**, 6, 190-8	11.7	31

50	Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice. *Radiology*, **2002**, 223, 417-25	20.5	66
49	Synthesis of the first diethylenetriaminepentahydroxamic acid (DTPH) bifunctional chelating agent. *Bioconjugate Chemistry*, **2002**, 13, 327-32	6.3	6
48	De novo synthesis of a new diethylenetriaminepentaacetic acid (DTPA) bifunctional chelating agent. *Bioconjugate Chemistry*, **2002**, 13, 317-26	6.3	21
47	Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. *Cancer Research*, **2002**, 62, 773-80	10.1	83
46	A noninvasive reporter system to image adenoviral-mediated gene transfer to ovarian cancer xenografts. *Gynecologic Oncology*, **2001**, 83, 432-8	4.9	47
45	An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. *Molecular Therapy*, **2001**, 4, 223-31	11.7	113
44	Gene therapy for the treatment of cancer. *Cancer Biotherapy and Radiopharmaceuticals*, **2001**, 16, 275-88	3.9	12
43	Simultaneous evaluation of dual gene transfer to adherent cells by gamma-ray imaging. *Nuclear Medicine and Biology*, **2001**, 28, 135-44	2.1	27
42	Experimental radioimmunotherapy. *Seminars in Radiation Oncology*, **2000**, 10, 156-67	5.5	22
41	A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. *Molecular Therapy*, **2000**, 2, 562-78	11.7	183
40	An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian cancer. *Molecular Therapy*, **2000**, 1, 545-54	11.7	57
39	A robust summarize-regress procedure for tissue-specific pharmacokinetics. *Journal of Biopharmaceutical Statistics*, **2000**, 10, 251-64	1.3	
38	Radionuclide Dosimetry and Radioimmunotherapy of Cancer **2000**, 21-55		1
37	Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. *Cancer Biotherapy and Radiopharmaceuticals*, **1999**, 14, 451-63	3.9	119
36	Improved synthesis of the bifunctional chelating agent 1,4,7,10-tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N′,N″,N‴-tri s(acetic acid)cyclododecane (PA-DOTA). *Bioorganic and Medicinal Chemistry*, **1999**, 7, 2313-20	3.4	40
35	Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors. *Cancer Gene Therapy*, **1999**, 6, 209-19	5.4	27
34	Further studies on the protein conjugation of hydroxamic acid bifunctional chelating agents: group-specific conjugation at two different loci. *Bioconjugate Chemistry*, **1999**, 10, 18-23	6.3	13
33	Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes. *Journal of Medicinal Chemistry*, **1999**, 42, 4919-24	8.3	88

32	Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer. *Current Opinion in Oncology*, **1999**, 11, 187-90	4.2	12
31	Combined cytosine deaminase expression, 5-fluorocytosine exposure, and radiotherapy increases cytotoxicity to cholangiocarcinoma cells. *Journal of Gastrointestinal Surgery*, **1998**, 2, 283-91	3.3	14
30	Radiosensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo. *International Journal of Radiation Oncology Biology Physics*, **1998**, 42, 817-22	4	20
29	Synthesis and biodistribution of peptide based 99mTc/186Re-MAGIPG-D612 monoclonal antibody in nude mice bearing colon cancer xenografts. *Cancer Biotherapy and Radiopharmaceuticals*, **1997**, 12, 55-62	3.9	3
28	Conjugation of unprotected trisuccin, N-[tris[2-[(N-hydroxyamino)carbonyl]ethyl]methyl]succinamic acid, to monoclonal antibody CC49 by an improved active ester protocol. *Bioconjugate Chemistry*, **1997**, 8, 766-71	6.3	5
27	Synthesis, rhenium-188 labeling and biodistribution studies of a phenolic ester derivative of trisuccin. *Cancer Biotherapy and Radiopharmaceuticals*, **1997**, 12, 375-84	3.9	1
26	Synthesis of bombesin analogues for radiolabeling with rhenium-188. *Cancer*, **1997**, 80, 2354-2359	6.4	38
25	Experimental tumor targeting with radiolabeled ligands. *Cancer*, **1997**, 80, 2371-2377	6.4	21
24	Tumor localization of a radiolabeled bombesin analogue in mice bearing human ovarian tumors induced to express the gastrin-releasing peptide receptor by an adenoviral vector. *Cancer*, **1997**, 80, 2419-2424	6.4	19
23	Dosimetric comparison of bolus and continuous injections of CC49 monoclonal antibody in a colon cancer xenograft model. *Cancer*, **1997**, 80, 2567-2575	6.4	8
22	Synthesis of a new class of isothiocyanatopeptide bifunctional chelating agents for coupling to monoclonal antibodies. *International Journal of Peptide and Protein Research*, **1996**, 48, 79-86		1
21	A quantitative study of radionuclide characteristics for radioimmunotherapy from 3D reconstructions using serial autoradiography. *International Journal of Radiation Oncology Biology Physics*, **1996**, 35, 165-72	4	11
20	Dosimetry of Radiolabeled Antibodies. *Medical Radiology*, **1995**, 365-384	0.2	1
19	A peptide-based bifunctional chelating agent for 99mTc- and 186Re-labeling of monoclonal antibodies. *Cancer*, **1994**, 73, 769-73	6.4	18
18	Radioiodination of monoclonal antibodies D612 and 17-1A with 3-iodophenylisothiocyanate and their biodistribution in tumor-bearing nude mice. *Cancer*, **1994**, 73, 808-15	6.4	14
17	Three-dimensional reconstruction of monoclonal antibody uptake in tumor and calculation of beta dose-rate nonuniformity. *Cancer*, **1994**, 73, 912-8	6.4	19
16	Sensitization of radiolabeled monoclonal antibody therapy using bromodeoxyuridine. *Cancer*, **1994**, 73, 999-1005	6.4	19
15	Synthesis of N-[tris[2-[[N-(benzyloxy)amino]carbonyl]ethyl]methyl]succinamic acid, trisuccin. Hydroxamic acid derivatives as a new class of bifunctional chelating agents. *Bioconjugate Chemistry*, **1993**, 4, 194-8	6.3	10

14	Experimental radioimmunotherapy. *Medical Physics*, **1993**, 20, 551-67	4.4	46
13	Introduction: radiolabeled antibody tumor dosimetry. *Medical Physics*, **1993**, 20, 499-501	4.4	5
12	Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts. *International Journal of Radiation Oncology Biology Physics*, **1993**, 25, 629-38	4	28
11	New azomycin acyclonucleoside. Synthesis and biodistribution of radiohalogenated analogues in tumor-bearing mice. *Journal of Heterocyclic Chemistry*, **1993**, 30, 1351-1355	1.9	5
10	Development of 3-iodophenylisothiocyanate for radioiodination of monoclonal antibodies. *International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes*, **1992**, 43, 1387-91		3
9	Three-dimensional tumor dosimetry for radioimmunotherapy using serial autoradiography. *International Journal of Radiation Oncology Biology Physics*, **1992**, 24, 329-34	4	30
8	18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. *Cancer*, **1991**, 67, 1544-50	6.4	177
7	A sensitivity study of micro-TLDs for in vivo dosimetry of radioimmunotherapy. *Medical Physics*, **1991**, 18, 1195-9	4.4	8
6	Comparison of antigen expression on normal urothelial cells in tissue section and tissue culture. *Journal of Urology*, **1990**, 144, 1288-92	2.5	37
5	A comparison of 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts. *International Journal of Radiation Oncology Biology Physics*, **1990**, 18, 1033-41	4	40
4	Human leukemia cell binding and killing by anti-CD5 radioimmunotoxins. *International Journal of Radiation Oncology Biology Physics*, **1987**, 13, 1701-12	4	6
3	Comparison of the distribution and binding of monoclonal antibodies labeled with 131-iodine or 111-indium. *European Journal of Nuclear Medicine and Molecular Imaging*, **1985**, 10, 398-402		14
2	Localization of radiolabeled antibody in SVT2 tumor increases with immunosuppression of the host. *Experimental Biology and Medicine*, **1982**, 171, 56-64	3.7	1
1	Localization of an 125 I-labeled rat transplantation antibody in tumors carrying the corresponding antigen. *Experimental Biology and Medicine*, **1972**, 139, 1185-8	3.7	12